• Product NameTAK-715
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityTAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. Phase 2.
• Target NameJNK inhibitor; p38 MAPK inhibitor
• CAS No. 303162-79-0
• Calculated MW 399.51
• Formulation C24H21N3OS
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CCC1=NC(=C(S1)C1=CC(NC(=O)C2=CC=CC=C2)=NC=C1)C1=CC=CC(C)=C1 |c:4,16,18,20,22,27,30,t:2,8,14,25|
  Pathways:MAPK
  Receptor:JNK1; p38α; p38β; p38γ; p38δ
  Boling pt:
  Melting pt:
  Solubility:DMSO:80 mg/mL (200.24 mM)Ethanol:16 mg/mL (40.04 mM)Water:<1 mg/mL (<1 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Miwatashi S, et al. J Med Chem, 2005, 48(19), 5966-5979.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting